Share on LinkedInShare on LinkedIn

ARTICLE · 10 JULY 2025

Final Guidelines From Canada's PMPRB: The New Era Begins

Torys
Torys
Contributor
Torys

Torys

Torys LLP is an international business law firm that works with clients who expect the best advice...

View firm profile
Explore more from Torys

On June 30, 2025, the PMPRB published final non-binding guidelines (Guidelines) titled Guidelines for PMPRB Staff: Administrative Process for Excessive Price Hearing Recommendation.

CanadaIntellectual Property

On June 30, 2025, the PMPRB published final non-binding guidelines (Guidelines) titled Guidelines for PMPRB Staff: Administrative Process for Excessive Price Hearing Recommendation1. The Guidelines will operationalize the requirements of the Patented Medicines Regulations (PMR) that were amended and came into force in 2022 following judicial decisions on their scope.

What you need to know

  • The Guidelines are final and will come into effect on January 1, 2026. The PMPRB has been operating under interim guidance as a temporary measure while final Guidelines were being developed, and no price reviews have been conducted during this interim period.
  • Patented medicines that were approved prior to July 1, 2022 (Existing Medicines) will undergo a first annual review in January 2028, and the price will only be assessed against the highest international price (HIP) of the basket of 11 countries specified as comparators in the PMR (the PMPRB11) at that time2. Only if

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from